Trends & Forecasts

A report attempts to unravel the many challenges that face business leaders. We discuss those inherent in the pharmaceutical industry.

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”

The FDA says it wants to phase out mandatory animal testing requirements for drug approval. What comes next?

We ask an analyst how pharma companies can weather the volatile economic environment and the Trump administration’s tariffs.

Trump continues to send shockwaves through the industry. We look at FDA disruption, tariffs, funding volatility, and more.

Many US researchers are at odds with the imposition of Trump’s political agendas. EU member states are looking to take advantage.

Can making clinical trials more family friendly help increase the number of female participants?

As mental health disorders escalate, pharmaceutical innovators can harness advanced tools to accelerate much-needed treatments.

Our latest news roundup reports on Roche’s US investment, a lawsuit against Vertex Pharmaceuticals, and more.

EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.